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Introduction: The potential for an ultrasound based screening programme for renal cell carcinoma 
(RCC) to improve survival through early detection has been the subject of much debate. The 
prevalence of ultrasound detected asymptomatic RCC is an important first step to establishing 
whether a screening programme may be feasible.  
 
Methods: A systematic search of Medline and Embase was performed until March 2016 to identify 
studies reporting the prevalence of renal masses and RCC. Two populations of patients were chosen, 
asymptomatic individuals undergoing screening ultrasonography and patients undergoing 
ultrasound for abdominal symptoms not related to RCC. A random effects meta-analysis was 
performed. Study quality was evaluated using a validated 8-point checklist. 
 
Results: Sixteen studies (n=414 266) were included in the final analysis. The pooled prevalence of 
renal masses was 0.36% (95% CI 0.23-0.52%) and the prevalence of histology-proven RCC was 0.10% 
(95% CI 0.06-0.15%). The prevalence of RCC was more than double in studies from Europe and North 
America compared to Asia (0.17% (0.09-0.27%) vs 0.06% (0.03-0.09%)). Data on 205 screen-detected 
RCCs demonstrated that 84.5% of tumours were stage T1-T2, 13.5% were T3-T4, and only 2% had 
positive nodes or metastases at diagnosis.  
 
Conclusion: At least one renal cell carcinoma would be detected per 1 000 individuals screened. The 
majority of tumours identified are early stage (T1-T2).   
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Introduction 
 
Overall survival from renal cell carcinoma (RCC) is poor, with a 47% five-year age 
standardized relative survival rate in the United Kingdom 
1
. Half of all patients with renal cancer 
present with asymptomatic disease and therefore many cancers are detected late, with over a 
quarter of individuals diagnosed with RCC having evidence of metastases at presentation 
2, 3
. 
Patients with metastases have a 6% five-year (age standardized relative) survival rate compared to 
84% survival in patients with stage one disease 1. Incidentally detected tumours are generally smaller 
in size and are associated with improved survival relative to symptomatic tumours, independent of 
tumour grade and stage 4, 5. A screening programme consisting of abdominal ultrasound, potentially 
in a selected higher risk population, in theory could improve survival outcomes through early 
detection and treatment of RCC. Previously, the low prevalence of renal cancer in the general 
population and relatively poorly understood natural history of renal masses were considered major 
barriers to establishing a cost effective screening service 
6
. More recently, there has been a 
resurgence in interest in a screening programme for RCC 7.  The established abdominal aortic 
aneurysm (AAA) screening programme in men over the age of 65 years in the United Kingdom 
represents an ideal model to explore the possibility of screening for RCC due to the similarities in risk 
factors and mode of detection between RCC and AAA 
8
. Furthermore, it has been postulated that 
early detection of asymptomatic RCC through a targeted national screening programme may 
potentially downstage the disease, reducing the prevalence of metastatic tumours and associated 
expenditure relating to systemic therapies.  Although a number of drugs for the treatment of mRCC 
are available they are very expensive 9-11.   
Prior to consideration of a screening study for RCC it is essential to assess potential cost 
effectiveness, by assembling all relevant evidence on the incremental costs and consequences of 
screening into an economic model. One of the key parameters that will inform cost-effectiveness is 
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the prevalence of renal masses and RCC in a screened population 
12
; therefore, in this study, a 
systematic review and meta-analysis was performed to determine RCC prevalence.   
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Methods 
 
Data sources and search strategy 
 
The study protocol was registered on the PROSPERO database 
(http://www.crd.york.ac.uk/PROSPERO/ ; CRD42016036899) and the study conducted in accordance 
with PRISMA guidelines (Table S1). A systematic literature search was performed in Medline (January 
1976-March 2016) and Embase (January 1976-March 2016) databases. Full details of the keywords 
and subject headings used are available in supplemental table S2. The reference list of all relevant 
articles was manually reviewed.  
 
Inclusion and exclusion criteria 
 
Study inclusion, data extraction and data quality assessments were performed 
independently by two reviewers (SHR and RH), with discrepancies resolved by a third investigator 
(GDS). Full inclusion and exclusion criteria are reported in Table S3. Studies were included in the 
analysis if the prevalence of renal masses and/or RCC was reported in asymptomatic individuals 
undergoing abdominal ultrasound (“screening” group), patients undergoing abdominal ultrasound 
for a medical reason not related to RCC (“incidental finding” group) or the study comprised a 
combination of both screened as well as non-screened individuals (“mixed” group).  Studies were 
excluded if ultrasound was performed in individuals that did not represent a general adult 
population or if patients had symptoms of renal cancer (flank pain, abdominal mass, non-visible 
and/or visible haematuria). Patients undergoing ultrasound for suspected renal colic were also 
excluded as symptoms may have been secondary to RCC rather than renal stones. Studies which 
performed ultrasound screening in individuals with familial syndromes predisposing to RCC or 
patients with renal transplant or end stage renal disease were also excluded from the analysis. 
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Study Quality Assessment 
 
A validated checklist was utilized to assess the quality of studies reporting the prevalence of 
renal masses in a screening population, with studies scored out of a total of 8 points 
13
. Item 6 on the 
checklist evaluates whether the studies reported the participation rate of individuals invited to 
attend screening. Studies reporting the prevalence of incidental renal masses in patients undergoing 
ultrasonography for a non-urological complaint were assessed on a modified 7-point checklist, as 
Item 6 was no longer a valid item in this group. Item 3 on the checklist evaluates whether the study 
sample size was sufficient to estimate prevalence with an adequate level of confidence and 
precision. Studies were awarded a point if they included more than 5 107 participants (sample size 
calculation appendix 1). Study quality was used to perform subgroup analysis. No studies were 
excluded from the meta-analysis based on quality score or sample size. 
 
Study outcomes 
 
The primary study outcomes were the prevalence of solid or complex cystic renal masses 
suspicious for RCC on ultrasound and the prevalence and stage distribution of histology-proven RCC 
in asymptomatic individuals. The secondary outcome was the prevalence of other renal and adrenal 
pathology. Pre-planned subgroup analysis consisted of study type (i.e. screening, mixed or incidental 
finding), study geographical region of origin, publication year and study quality.  The prevalence of 
RCC by established risk factors such as age, gender, hypertension, smoking and body mass index 
(BMI) was assessed. 
 
Statistical analysis 
 
The statistical analysis was performed using Stata version 12.0 (Stata Corp, College Station, 
TX). The meta-analysis was performed on the double arcsine transformation (appendix 2) for each 
proportion, using the generic inverse variance method. The double arcsine transformation stabilizes 
the variance and is particularly useful for proportions which are at the extremes of the 0 to 1 range, 
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as is the case for an uncommon condition such as RCC 
14
. In this case, asymmetrical confidence 
intervals are created to avoid reporting a prevalence in the negative range. As such, it is not 
appropriate to use funnel plots to assess for publication bias, as the typical funnel shape relies on 
symmetry of confidence intervals. Heterogeneity was assessed using the chi-square test and the I-
squared (Cochran’s Q) statistic. The pooled prevalence was calculated using a random-effects model 
due to significant study heterogeneity. Meta-regression was used to assess the association between 
study characteristics (including study type, size, publication year and geographical region) and the 
prevalence of RCC. A p value of < 0.05 was reported as statistically significant.  
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Results 
Data retrieval and study quality 
 
Following exclusion of duplicates, the search yielded 2658 articles. Sixteen studies were 
included in the final meta-analysis for renal masses (n=414 266 individuals) (Figure 1 and Table 1). 
The median quality score for studies in the screening and mixed groups was 4 (range 3-6) out of a 
potential 8 points, whereas studies in the non-screening group only achieved a median score of 1.5 
(range 1-3) out of a potential 7 points (Table S4). All studies were observational in nature, consisting 
of one study arm alone (i.e. no non-screening comparator), and none utilised a random sampling 
method. Only one study commented on the participation rate of individuals invited to attend 
screening 
15
. None of the studies reported 95% confidence intervals (CI) for point estimates of 
prevalence, despite the fact that this was an item on the quality assessment checklist (although this 
is readily calculable, given knowledge of the sample size). Three studies did not clearly state 
ultrasound criteria used to define a suspicious renal mass and three further studies only included 
solid (rather than complex cystic) masses in this definition. Five studies reported data on the 
prevalence of renal masses, but no histological data was available, therefore these studies were 
excluded from the analysis of the prevalence of histology-proven RCC. All studies reporting the 
prevalence of histology-proven RCC were based on operative (rather than biopsy) specimens. 
 
Primary outcomes  
 
The pooled prevalence of renal masses was 0.36% (95% CI 0.23-0.52%; (Figure 2). The 
pooled prevalence of histology-proven RCC was 0.10% (95% CI 0.06-0.15%; Figure 3). Significant 
study heterogeneity was noted for both outcomes (Chi2 327.60, d.f.=15, p<0.00001, I2 96% and Chi2 
112.62, d.f.=11, p<0.00001, I2 91%). Out of the 10 studies investigating the prevalence of screen-
detected RCC, a wide variability in the method used for reporting the size and stage of the tumours 
was noted. Only 3 studies reported data on the TNM staging of the detected RCCs 8, 15, 16, with two of 
these using TNM 1992 classification and one using TNM 1997. Two studies reported staging by 
Page 9 of 47
http://mc.manuscriptcentral.com/bjs
BJS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR REVIEW ONLY
10 
 
 
 
Robson’s classification 
17, 18
 and three studies reported individual tumour size but not tumour stage 
19-21. Differences in reporting of data limited the ability to pool results on the size and stage of 
screen-detected RCC, and therefore three different grouping methods were used (Table S5). Data on 
66 cancers from four studies were pooled to reveal that 45% of screen detected cancers were ≤4cm, 
41% RCCs were between 4 and 7cm, with only 14% over 7cm in size 
8, 15, 21
. Similarly, data on 185 
screen detected RCCs from two further studies demonstrated 80% of tumours were less than 5cm in 
size 16, 20. In addition, pooling data on 205 screen-detected RCCs from three studies showed that 
84.5% of tumours were stage T1 or T2, 13.5% RCC were T3-T4N0, and only 2% had positive lymph 
nodes or metastases at diagnosis (TNM 1992 classification) 8, 15, 16.  
 
Secondary outcomes   
 
A number of additional renal and adrenal pathologies were identified among the studies 
(Table S6). Of note, Mihara et al reported detection of an additional 5 (prevalence 0.0023%) 
malignant, non-RCC kidney lesions in addition to the cases of RCC (prevalence 0.086%) 16. Due to 
heterogeneity of reported data, only the prevalence of asymptomatic hydronephrosis and renal 
stones were pooled in a meta-analysis (Supplemental figure S1 and S2). The pooled prevalence of 
hydronephrosis was 0.48% (95% CI 0.21-0.87%, Chi
2
 = 76.75, df= 5, p<0.00001, I
2
 =95%) and the 
prevalence of asymptomatic renal stones was 1.8% (95% CI 0.59-3.6%, Chi2 = 844.78, df= 9, 
p<0.00001, I2 =100%).  
 
Subgroup analysis 
The geographical region in which the study was undertaken was the only subgroup that 
consistently affected the prevalence of renal masses and histology proven RCC (Table 2). However, 
assessing the prevalence by study geographical region did not reduce heterogeneity. The prevalence 
of renal masses and RCC was more than double in studies from Europe and North America compared 
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to studies from Asia (renal mass: 0.70% (95% CI 0.31-1.22%) vs 0.30% (95% CI 0.14-0.52%); RCC 
0.17% (95% CI 0.09-0.27%) vs 0.06% (95% CI 0.03-0.09%)). Geographical region was a significant 
determinant of the prevalence of RCC in meta-regression (p=0.002) but notably study type and 
quality were not (p=0.876 and p=0.432 respectively; Table S7). The effect of publication year, study 
type and study quality was not consistent across the two outcomes. The pooled prevalence of renal 
masses was higher in the non-screening subgroup compared to the screening subgroup (0.73% (95% 
CI 0.31-1.3%) vs 0.25% (95% CI 0.17-0.35%)); however, this pattern was not noted in terms of the 
prevalence of RCC, with lower prevalence of cancer in the non-screening compared to the screening 
subgroup (0.05% (95% CI 0.00-0.16%) vs 0.11% (95% CI 0.06-0.17%)).There was insufficient data to 
assess the impact of established risk factors for the development of RCC, i.e. patient age, 
hypertension, smoking status and BMI on the prevalence of cancer. Only five studies reported 
sufficient data to allow a calculation of the prevalence of RCC by gender 
8, 15, 19, 20, 22
. The pooled 
prevalence of RCC was higher in men compared to women (0.09% (95% CI 0.03-0.18%) vs 0.01% 
(95% CI 0-0.05%)). 
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Discussion 
Early detection and screening for cancer has been identified as a key priority for the National 
Health Service, with increased resource allocation and media coverage 
23
. Though the UK National 
Screening Committee has released recommendations regarding screening for colorectal, breast, 
prostate, ovarian and lung cancer, screening for RCC has yet to be discussed as there is currently 
incomplete data, with relatively little research published in the literature over the last decade 
2, 24
. 
Data on the prevalence of RCC in asymptomatic individuals undergoing abdominal ultrasonography 
is lacking, but is essential to inform an economic evaluation of the cost effectiveness of an 
ultrasound based screening programme. Here a pooled prevalence of renal masses of 0.36% (95% CI 
0.23-0.52%) with a pooled prevalence of histology-proven RCC of 0.10% (95% CI 0.06-0.15%) was 
demonstrated. Current National Cancer Intelligence Network data suggest that although 44% of 
patients diagnosed with RCC are stage 1 at presentation, only 10% are stage 2, with over 25% having 
metastases 
25
. The meta-analysis showed that 84.5% of screen-detected tumours were stage T1 or 
T2, 13.5% were T3, and only 2% had positive nodes or metastases at diagnosis, suggesting a 
potential favourable stage shift in screen-detected disease.  
 
It is anticipated that focused screening renal ultrasonography will lead to detection of other 
benign and malignant renal and adrenal abnormalities. The prevalence of screen-detected 
hydronephrosis was estimated to be 0.48% (95% CI 0.21-0.87%) and renal stones 1.8% (95% CI 0.59-
3.6%). Unfortunately, there was insufficient data to estimate the pooled prevalence of benign 
masses of the renal fossa, such as angiomyolipoma and oncocytoma, nor the prevalence of renal 
cysts, the most common screen-detected renal pathology. The prevalence of asymptomatic cysts is 
estimated to be 30% in individuals aged >70 years 26. A proportion of screen-detected cysts may 
require further imaging, discussion with a specialist and potentially treatment. An evaluation of a 
screening programme for RCC must take into consideration the impact of incidentally detected 
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benign renal lesions on patients and health services. There is a potential for false positive results and 
over-diagnosis of slow-growing small renal masses (SRM). Currently, 15-30% of SRM are found to be 
benign following surgical excision 
27-29
. Advances in the determination of the aetiology of SRMs, with 
increased utilization and better interpretation of renal biopsy, may reduce these rates in future 30. 
Up to one third of small renal cancers exhibit aggressive potential (rapid growth or doubling time 
<12 months), with the remainder growing slowly or remaining stable in size
31, 32
. It is anticipated that 
in future, the development of non-invasive modalities, such as urinary biomarkers, will allow 
improved discrimination between benign and malignant SRM (with further differentiation between 
indolent and aggressive RCC), enabling personalised treatment strategies and reducing over-
treatment 
33
.These considerations may be further offset by the potential benefit derived from early 
detection of other malignancies within the renal fossa (including adrenal and upper urinary tract 
urothelial cell cancers, renal secondary metastases, renal carcinoid, sarcoma and lymphoma). 
Spouge et al reported the prevalence of these combined malignancies as 0.2%, whereas Mizuma et 
al, Malaeb et al and Patel et al all reported a prevalence of 0.03% 8, 19, 34. These rates vary 
considerably and unfortunately insufficient data was available to complete a meta-analysis. Further 
studies are needed to quantify this and to estimate the potential impact on health services. 
 
It is likely that this meta-analysis underestimated the true prevalence of histology-proven 
RCC.  Several studies reported a higher prevalence of suspected RCC, however due to patient loss to 
follow up or contra-indications to surgery, histological confirmation was only available in a portion of 
these 8, 15, 16, 20. For example, Malaeb et al screened 6 678 individuals with ultrasound and 
confirmatory CT demonstrated 22 solid renal masses suspicious for RCC, however histology was only 
available in 15 of these cases (68%), potentially underestimating the true prevalence of malignancy 8. 
Furthermore, only half of the studies included in the meta-analysis represented a European or North 
American population, with the remainder of studies originating from Asia or the Middle East. Our 
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results suggest that there is significant variability between the prevalence of screen-detected RCC in 
different geographical areas, in keeping with known epidemiological data 35. The prevalence of RCC 
in studies originating from Europe and North America (0.17%; 95% CI 0.09-0.27%) was more than 
double the prevalence in Asia (0.06%; 95% CI 0.03-0.09%). Another factor that may have contributed 
to a potential underestimation of the true prevalence of RCC is the young age of the screening study 
participants. Only 1 out of 8 screening studies reported a participant mean age over 65 years and 5 
out of 8 studies included individuals under the age of 30 years. Young patients with RCC are at 
greater risk of familial syndromes predisposing to cancer, however due to lack of patient level data, 
it was not possible to exclude young participants by age from the analysis. In addition, the included 
studies were published between 1982 and 2010, with over 80% (13 out of 16) published prior to 
2006. Such factors restrict the applicability of these results to the population of interest in the 
United Kingdom, and highlight the need for more high quality research in a contemporary Western 
population. Obesity and older age are established risk factors for the development of RCC 
36, 37
, and 
with the rising obesity epidemic and aging population, the incidence of RCC is expected to rise in 
future.  
This meta-analysis included relatively low quality studies. The retrospective design and 
substantial rates of loss to follow-up should all be taken into consideration when interpreting the 
results. In addition, there were discrepancies in the ultrasound criteria used to define a renal mass in 
different studies. Importantly, none of the studies compared a screening intervention to a non-
screening group or used a random sampling method to select study participants. In addition, 
methods utilised by the studies to recruit participants may also introduce bias within the “screening 
group.” For example, two studies offered abdominal ultrasound to asymptomatic individuals as part 
of an employee health check-up, rather than screening individuals through a population registry. The 
inclusion of studies assessing the prevalence of renal cancer in patients undergoing abdominal 
ultrasound for a medical reason not related to kidney cancer (“incidental finding” group) may have 
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introduced heterogeneity in the data. These smaller studies are also more prone to potential 
publication bias. However, neither study type nor study quality score were found to be significant 
factors in meta-regression and further, heterogeneity remained high even when pooling only 
screening population studies. The persistent heterogeneity may in part be attributed to differences 
in study design and patient populations. The included studies reported only limited data on the 
prevalence of renal cancer by established risk factors, precluding any formal analysis. Though, as 
expected, the prevalence of RCC was found to be higher in males compared to females, it is likely 
that due to small sample sizes the estimate of effect size is inaccurate, hindering conclusions 
regarding the potential for targeted screening.  
 
The results of this meta-analysis on the prevalence of RCC detected by ultrasound is broadly 
in keeping with what would be expected from the data published for screening non-contrast CT. Two 
studies have attempted to pool data from the literature to quantify the prevalence of renal cancer in 
asymptomatic individuals, and both of these utilised non-contrast CT rather than ultrasound as a 
screening tool. Fenton et al calculated the pooled prevalence of renal cancer in asymptomatic 
American patients undergoing non-contrast screening CT as 0.21% (95% CI 0.14-0.28%) 38. Wernli et 
al estimated the pooled prevalence of renal masses as 0.22% in patients undergoing non-contrast CT 
colonography; with a rate of 0.06% in screened populations and 0.42% in non-screening populations 
39. Conversely, ultrasound is known to be less sensitive and specific compared to non-contrast CT for 
the detection of renal cancers; with ultrasound detection rates being dependent on renal lesion size, 
a factor that would need to be considered in the design of a screening programme in terms of 
frequency of ultrasound scanning 
40
. Studies examining autopsies or cadaveric organ donors 
estimate a prevalence of RCC of 0.7% to 0.9% (mean age of study participants: 65 years) 41, 42. This is 
substantially higher than the prevalence suggested by the meta-analysis, raising once again the 
possibility that the true prevalence of histology-proven RCC may have been under-estimated. 
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This meta-analysis suggests that screening 1 000 individuals would result in 4 patients 
undergoing further imaging of a renal mass, and that at least 1 of these patients would be diagnosed 
with RCC. The clinical significance of these findings is best appreciated in the context of other 
established screening programmes (Figure 4). The UK AAA screening programme identifies 10 men 
with an AAA >3cm for every 1 000 individuals screened. However, only 2 men receive elective 
surgery to repair a large AAA following initial screening 43.  An additional 6 individuals require 
elective surgery to repair a large AAA following active surveillance over a twenty year period 
44
. 
Results from the Bowel Cancer Screening Programme in England demonstrate that 1.6 colorectal 
cancers are detected for every 1 000 individuals screened using guaiac-based faecal occult blood 
tests. An additional 6 cases are detected with high risk adenomatous polyp requiring surveillance 
colonoscopy
45
. The UK Breast Cancer screening programme detection rate is 8.3 per 1 000 women 
screened 
46
. This number is much higher than the projected values for RCC screening, however it is 
estimated that 15% to 25% of screen-detected breast cancers consist of over-diagnosis 47. Screening 
for RCC may compare favourably to the established programmes for AAA and colorectal cancer, 
although intrinsic differences underlying each screening programme and the individual nature of 
each disease make direct comparisons artificial.  
 
In isolation, this meta-analysis is insufficient to support or refute a screening programme for 
RCC and should not replace a full consideration of the Wilson-Jungner criteria 
49
. A cost effectiveness 
analysis is beyond the scope of this paper, but should constitute an essential next step towards 
establishing the potential value of screening.  
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Figure legends 
Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow 
diagram demonstrating study search strategy. 
Figure 2: Forest plot demonstrating the pooled prevalence of suspicious renal masses detected by 
ultrasonography, generated by a random effects meta-analysis. Results are shown in three 
subgroups: screening population, incidental finding and mixed. Study author, year, the number of 
renal masses (n) and the total number of study participants (N) are shown. Prevalence (n/N) is 
demonstrated as a percentage, labelled as ES (effect size) along with 95% confidence intervals (CI).  
Figure 3: Forest plot demonstrating the pooled prevalence of histology-proven RCC (renal cell 
carcinoma) detected by ultrasonography, generated by a random effects meta-analysis. Results are 
shown in three subgroups: screening population, incidental finding and mixed. Study author, year, 
the number of renal cancers (n) and the total number of study participants (N) are shown. 
Prevalence (n/N) is demonstrated as a percentage, labelled as ES (effect size) along with 95% 
confidence intervals (CI). 
Figure 4: Infographic delineating comparative detecting ability of established UK screening programs 
versus screening for renal cell carcinoma. Our meta-analysis suggests screening 1 000 individuals 
would detect at least 1 renal cell carcinoma (green). Screening 1 000 individuals detects 1.6 
colorectal cancers (blue), 8 breast cancers (pink) and 10 abdominal aortic aneurysms ≥ 3cm (red). 
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Table legends 
Table 1: Characteristics of included studies 
 
Table 2: Subgroup analysis for the pooled prevalence of renal masses and histology-proven renal cell 
carcinoma (RCC) 
Figure legends: Supplementary figures 
Figure S1: Forest plot demonstrating the pooled prevalence of hydronephrosis detected by 
ultrasonography, generated by a random effects meta-analysis. Results are shown in two subgroups: 
screening population and incidental finding. Study author, year, the number of cases of 
hydronephrosis (n) and the total number of study participants (N) are shown. Prevalence (n/N) is 
demonstrated as a percentage, labelled as ES (effect size) along with 95% confidence intervals (CI).  
Figure S2: Forest plot demonstrating the pooled prevalence of renal stones detected by 
ultrasonography, generated by a random effects meta-analysis. Results are shown in two subgroups: 
screening population and incidental finding. Study author, year, the number of cases of renal stones 
(n) and the total number of study participants (N) are shown. Prevalence (n/N) is demonstrated as a 
percentage, labelled as ES (effect size) along with 95% confidence intervals (CI).  
 
Table legends: Supplementary tables 
Supplementary Table S1: Completed Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist  
 
Supplementary Table S2: This table illustrates the review search strategy. Medline and Embase were 
searched, using the Ovid platform. Key words and Medical Subject Headings (MeSH) used are shown, 
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where $ indicates right-hand truncation (i.e., search for variations on a word that are formed with 
different suffixes) and ? is used to retrieve words with both British and American spelling variations. 
All searches were limited to humans and publications in the English language.  
 
Supplementary Table S3: Details of inclusion and exclusion criteria 
 
Supplementary Table S4: Assessment of methodological quality diagram, based on a validated 8-
point checklist described by Loney et al
13
. Green indicates that the study fulfilled the item on the 
checklist, whereas red indicates that the item was not met. Items are left blank when not relevant to 
the study type. 
 
Supplementary Table S5: Size and stage distribution of screen-detected renal cell carcinomas 
 
Supplementary Table S6: Prevalence of renal and adrenal pathology 
 
Supplementary Table S7: Meta-regression for prevalence of histology-proven renal cell carcinoma 
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Table 1 
 
 
Study 
(year) 
Country  Data collection 
dates 
Sample size Sample Recruitment Sample Demographics:  
Mean or median age (range), % male 
Fujii 
(1995)
22
 
Japan April 1985-  
March 1991 
17941  Asymptomatic individuals, 
Employee health check-up 
Median 53 years (21-85), 72% male. 
Spouge 
(1996)
18
 
Canada 6-month period, 
not specified 
1,000 Asymptomatic individuals, 
Employee health check-up for 
business executives 
Mean 46.2years (29-63), 91% male 
Spouge 
(1996) 
18
 
2
nd
 sample  
Canada 2.5-year period, 
not specified 
7,925 Asymptomatic individuals, 
Employee health check-up for 
business executives 
Not reported 
Mihara 
(1999)
16
 
Japan August 1983- 
March 1996 
219,640 Asymptomatic screening of 
general population 
Age range 29-70 years,  
Gender not reported 
Tsuboi 
(2000)
20
 
Japan January 1993-
June 1997 
60,604 Asymptomatic individuals, 
health check-up for the 
general population 
Age range 15-96, 67% male. 
Mizuma 
(2002)
19
 
Japan February 1990-
December 1995 
16,024 Asymptomatic individuals, 
health check-up for the 
general population  
Mean 47 years (25–84 years),  
58% male. 
Filipas 
(2003) 
15
 
 
Germany December 1996 
for 13 months 
and January 1998 
for 13 months 
9,959 Asymptomatic screening of 
general population, 
individuals aged >40 years 
Mean 61 years (40-94 years),  
49% male 
Malaeb 
(2004)
8
 
USA 1993-1997 6,678 Asymptomatic screening of 
veterans (in conjunction with 
AAA screen) 
Mean 66.2 years (50-79 years), 
97% male 
Mosharafa 
(2007)
50
 
Eight 
Middle 
Eastern 
countries 
January 2005-
December 2005 
 
8,551 
 
Asymptomatic individuals, 
health check-up for the 
general population 
Mean age 43.5 years (SD 13.9), 
70% male 
Tosaka 
(1990)
17
 
Japan 1982-1988 41,364  
(20,897 
screening+ 
20,467 non-
screening) 
Mixed: asymptomatic 
individuals (part of health 
check-up) and patients 
undergoing abdominal 
ultrasound for non-urological 
complaint 
Not reported 
Haliloglu 
(2010) 
21
 
Turkey March 1995- 
February 2008 
18,203 Mixed:  asymptomatic 
individuals (part of health 
check-up) and patients having 
ultrasound for LUTS 
55 years (33-90 years), 64% male. 
Fields 
(1985)
51
 
USA Not reported 500  Abdominal ultrasound for 
non-urological complaint 
Not reported 
Bodner 
(1990)
52
 
USA Not reported 86 Spinal cord injury patients, no 
urological symptoms 
Mean 41.7 years, 99% male 
Al-Durazi 
(2003)
53
 
Bahrain January 2001-
December 2001 
100 Men with acute retention 
secondary to BPH 
Mean 67 years (54-96), 100% male 
Belani 
(2004)
54
 
USA 3 months, not 
specified 
600  
 
Abdominal ultrasound for 
non-urological complaint 
Mean 53 years (18-95), 32% male  
Heikkinen 
(2005)
55
 
Finland January 1993- 
January 1994 
400 Patients undergoing 
investigations for dyspepsia 
Mean 55.8 years (ENG), mean 58.3 
years (EPG), 38% male. 
Patel 
(2009)
34
 
UK April 1994-
February 2007 
3,976 
 
Men with LUTS 65 years (15-91), 100% male 
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28 
 
 
 
Abbreviations for table 1: AAA= abdominal aortic aneurysm; BPH= benign prostatic hyperplasia; 
ENG= Endoscopy negative group; EPG= Endoscopy positive group; LUTS= lower urinary tract 
symptoms; RCC= Renal cell carcinoma; UK = United Kingdom; USA= United States of America. 
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Table 2 
 
Subgroup Prevalence of renal masses 
(95% CI) 
Prevalence of histology-proven RCC 
(95% CI) 
Overall pooled prevalence 0.36% (0.23-0.52) 0.10% (0.06-0.15%) 
 
Study publication year   
Prior to the year 1999: 0.67% (0.31-1.1%) 
 
0.11% (0.06-0.18%) 
Between 2000 and 2004: 0.17% (0.07-0.30%) 
 
0.08% (0.02-0.17%) 
 
After the year 2005: 
 
0.32% (0.10-0.67%) 0.12% (0.04-0.23%) 
Study quality   
Studies with quality score ≥4: 0.28% (0.19-0.395) 
 
0.12% (0.07-0.18%) 
 
Studies with quality score <4: 
 
0.55% (0.22-0.99%) 0.03% (0- 0.09%) 
Geographical region   
Asia 0.30% (0.14-0.52%) 0.06% (0.03-0.09%) 
 
Europe and North America: 0.70% (0.31-1.22%) 
 
0.17% (0.09-0.27%) 
Middle East 0.16% (0-0.66%) 0.20% (0.14-0.27%) 
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Appendices 
Appendix 1: Sample size calculation for study quality assessment 
The following formula was utilized to calculate the adequate sample size (N) for prevalence studies, 
as previously described 56:  
 N= Z
2
 P (1-P) (1/d
2
) 
Where P is the estimated prevalence of renal masses of 0.3% 16 and Z is the statistic 
corresponding to a 95% confidence level. A less conservative definition of precision (d) was used due 
to the low prevalence, where d is equal to the prevalence divided by 2 .  
 
 
 
Appendix 2: The Freeman-Tukey double arcsine transformation
14
 
The double arcsine transformation (t) is derived using the following formula, where n is the 
number affected and N is total sample size and Var is the variance. 
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Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram 
demonstrating study search strategy.  
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Figure 2: Forest plot demonstrating the pooled prevalence of suspicious renal masses detected by 
ultrasonography, generated by a random effects meta-analysis. Results are shown in three subgroups: 
screening population, incidental finding and mixed. Study author, year, the number of renal masses (n) and 
the total number of study participants (N) are shown. Prevalence (n/N) is demonstrated as a percentage, 
labelled as ES (effect size) along with 95% confidence intervals (CI).  
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Figure 3: Forest plot demonstrating the pooled prevalence of histology-proven RCC (renal cell carcinoma) 
detected by ultrasonography, generated by a random effects meta-analysis. Results are shown in three 
subgroups: screening population, incidental finding and mixed. Study author, year, the number of renal 
cancers (n) and the total number of study participants (N) are shown. Prevalence (n/N) is demonstrated as 
a percentage, labelled as ES (effect size) along with 95% confidence intervals (CI).  
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Figure 4: Infographic delineating comparative detecting ability of established UK screening programs versus 
screening for renal cell carcinoma. Our meta-analysis suggests screening 1 000 individuals would detect at 
least 1 renal cell carcinoma (green). Screening 1 000 individuals detects 1.6 colorectal cancers (blue), 8 
breast cancers (pink) and 10 abdominal aortic aneurysms ≥ 3cm (red).  
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Supplementary Tables 
 
Supplementary Table S1 
Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4-5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Table S2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
6 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
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Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
7 
 
 
Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
Table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table S4 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot.  
Figures 2-3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  9-10 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Figures 2-3 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  10-11, 
Table S7 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
12 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
13-15 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
2 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
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Supplementary Table S2 
 
Search Database and dates Search terms 
Search #1 Medline 
(1976-March 2016)  
 
Kidney neoplasms (Medical Subject Heading) OR renal cell carcinoma OR RCC OR renal mass$ OR renal cancer OR renal neoplas$ OR renal tumo?r 
OR renal carcinoma OR kidney cancer OR kidney neoplas$ OR kidney tumo?r OR kidney carcinoma OR hypernephroma OR Grawitz tumor OR renal 
adenocarcinoma OR oncocytoma 
 
AND 
 
Mass screening (Medical Subject Heading) or screen$ 
 
AND 
 
Ultrasonography (Medical Subject Heading) OR ultraso$ 
Search #2 Medline 
(1976-March 2016)  
 
Kidney neoplasms (Medical Subject Heading) OR renal cell carcinoma OR RCC OR renal mass$ OR renal cancer OR renal neoplas$ OR renal tumo?r 
OR renal carcinoma OR kidney cancer OR kidney neoplas$ OR kidney tumo?r OR kidney carcinoma OR hypernephroma OR Grawitz tumor OR renal 
adenocarcinoma OR oncocytoma 
 
AND 
 
Mass screening (Medical Subject Heading) or screening 
Search #3 Medline 
(1976-March 2016)  
 
Kidney neoplasms (Medical Subject Heading) OR renal cell carcinoma OR RCC OR renal mass$ OR renal cancer OR renal neoplas$ OR renal tumo?r 
OR renal carcinoma OR kidney cancer OR kidney neoplas$ OR kidney tumo?r OR kidney carcinoma OR hypernephroma OR Grawitz tumor OR renal 
adenocarcinoma OR oncocytoma 
 
AND 
 
Incidental finding (Medical Subject Heading) OR incidental$ OR prevalence ((Medical Subject Heading) OR prevalence 
Search #4 Embase 
 (1976-March 2016) 
Kidney neoplasms (Medical Subject Heading) OR renal cell carcinoma OR RCC OR renal mass$ OR renal cancer OR renal neoplas$ OR renal tumo?r 
OR renal carcinoma OR kidney cancer OR kidney neoplas$ OR kidney tumo?r OR kidney carcinoma OR hypernephroma OR Grawitz tumor OR renal 
adenocarcinoma OR oncocytoma 
 
AND 
 
Screening (Medical Subject Heading) OR mass screening (Medical Subject Heading) OR cancer screening (Medical Subject Heading) OR screen$ 
 
AND 
 
Ultrasound (Medical Subject Heading) OR ultraso$ 
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Supplementary Table S3 
Inclusion Criteria Exclusion Criteria 
1) Study reporting prevalence of renal masses 
and/or renal cell carcinoma in asymptomatic 
individuals undergoing ultrasonography. 
 
2) Study reporting prevalence of renal masses 
and/or renal cell carcinoma in patients 
undergoing ultrasound for abdominal 
symptoms not related to renal cell 
carcinoma. 
 
3) Adult population (age >15 years) 
 
4) Publication year after 1976 
 
5) English language 
 
6) Where several studies reported data on the 
same population, only the larger and more 
recent of these was included in the analysis. 
1) Study in which ultrasound was performed in 
individuals that did not represent a general unselected 
adult population 
a. End stage renal failure 
b. Dialysis 
c. Renal transplant 
d. Von Hippel Lindau disease or familial 
syndromes predisposing to renal cancer 
 
2) Study in which ultrasound was performed in patients 
with symptoms suggestive of renal cancer 
a. Flank pain 
b. Abdominal mass 
c. Microscopic or macroscopic haematuria 
 
3) Study in which ultrasound was performed in patients 
with suspected renal colic (as symptoms may have 
been secondary to RCC rather than renal stone) 
 
4) Whilst calculating the pooled prevalence of 
hydronephrosis, we exclude data from studies on 
patients with lower urinary tract symptoms 1 as these 
may over-estimate the prevalence of this condition in 
a general population. 
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Supplementary Table S4 
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/
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Screening Population 
Fujii (1995) ⓿ ❶ ❶ ❶ ❶ ⓿ ⓿ ❶ 5/8 
Spouge (1996) ⓿ ❶ ❶ ❶ ❶ ⓿ ⓿ ⓿ 4/8 
Mihara (1999) ⓿ ❶ ❶ ❶ ❶ ⓿ ⓿ ⓿ 4/8 
Tsuboi (2000) ⓿ ❶ ❶ ❶ ❶ ⓿ ⓿ ❶ 5/8 
Mizuma (2002) ⓿ ❶ ❶ ❶ ❶ ⓿ ⓿ ⓿ 4/8 
Filipas (2003) ⓿ ❶ ❶ ❶ ❶ ❶ ⓿ ❶ 6/8 
Malaeb (2004) ⓿ ❶ ❶ ❶ ❶ ⓿ ⓿ ❶ 5/8 
Mosharafa (2007) ⓿ ❶ ❶ ⓿ ❶ ⓿ ⓿ ⓿ 3/8 
Mixed 
Tosaka (1990) ⓿ ⓿ ❶ ❶ ❶ ⓿ ⓿ ⓿ 3/8 
Haliloglu (2010) ⓿ ⓿ ❶ ❶ ❶ ⓿ ⓿ ❶ 4/8 
Incidental finding 
Fields (1985) ⓿ ⓿ ⓿ ⓿ ❶  ⓿ ⓿ 1/7 
Bodner (1991) ⓿ ⓿ ⓿ ⓿ ❶  ⓿ ⓿ 1/7 
Al-Durazi (2003) ⓿ ⓿ ⓿ ⓿ ❶  ⓿ ❶ 2/7 
Belani (2004) ⓿ ⓿ ⓿ ⓿ ❶  ⓿ ⓿ 1/7 
Heikkinen (2005) ⓿ ⓿ ⓿ ❶ ❶  ⓿ ⓿ 2/7 
Patel (2009) ⓿ ⓿ ⓿ ❶ ❶  ⓿ ❶ 3/7 
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Supplementary Table S5 
 
Data on tumour size Data on tumour size Data on tumour stage 
Total sample size: 66  
Source: 2-5 
 
<4cm: 30/66 =45% 
4-7cm: 27/66 =41% 
7-10= 7/66 =11% 
>10: 2/66= 3% 
Total: 185  
Source: 6, 7 
 
 
<5cm = 148/185=80% 
>5: 37/185= 20% 
Total sample size: 205 
TNM 1992 classification 
Source: 2, 3, 6 
 
T1= 65/205 = 32% 
T2 =108/205 = 52.5% 
T3N0=27/205 = 13% 
T4N0=1/205 = 0.5% 
T3N+=2/205=1% 
Metastases: 2/205 = 1% 
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Supplementary Table S6 
 
Study (year) Sample size 
N 
  
Prevalence of benign pathology 
n (%) 
Prevalence of malignant 
pathology 
n (%) 
Fuji (1995) 17941  1 (0.0056%) Renal leiomyoma  
1 (0.0056%) Renal hemangioma  
41 (0.23%) AML 
9 (0.05%) Stones  
24 (0.13%) Normal variant/Cyst 
7 (0.039%) Pseudotumour 
 
Total: 83 (0.46%) 
(note: 41 suspected AML but only 24 
real confirmed) 
 
Spouge (1996) 
 
1,000 8 (0.8%) AML 
21 (2.1%) Stones 
5 (0.5%) Hydronephrosis  
73 (7.3%) Simple cyst 
 
 
(But on follow up imaging none were 
confirmed hydronephrosis) 
(12 (1.2%) Complex cyst) 
1 (0.1%) TCC bladder 
1 (0.1%) Suspicious adrenal mass 
 
 
 
 
 
 
 
Suspicious Pancreatic mass:1 
Atypical hepatic hemangioma: 4 
Mihara (1999) 219,640 84 (0.038%) AML/other benign tumours 
59 (0.027%) Renal cysts  
5 (0.0023%) Borderline lesions 
4 (0.0018%) Deformity of the kidney 
 
 
1 (0.00046%) Renal pelvic cancer 
2 (0.00091%) Sarcoma 
1 (0.00046%) Renal carcinoid 
1 (0.00046%) Malignant 
lymphoma of the kidney 
 
228 HCC liver 
90 Gallbladder cancers 
68 Pancreatic cancers  
Tsuboi (2000) 60,604 24 (0.040%) AML 
2 (0.0033%) Stones 
2 (0.0033%) Complex cysts 
 
Mizuma (2002) 16,024 56 (0.35%) Hydronephrosis 
31 (0.19%) Renal abnormality requiring 
further investigation 
1 Bladder cancer 
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Filipas (2003)  
 
9,959 1 (0.010%) Oncocytoma 
9 (0.090%) AML 
13 (0.13%) Hydronephrosis 
214 (2.1%) Stones 
40 (0.40%) Renal anomaly (small kidney, 
dysplasia, aplasia) 
1264 (12.69%) Cyst/scar/duplex system 
 
Malaeb (2004) 6,678 627 (9.4%) Simple cysts 
21 (0.31%) Hydronephrosis 
121 (1.8%) Stones 
24 (0.36%) Other renal abnormality 
(horseshoe kidney, atrophy, duplication, 
renal calcifications) 
2 (0.030%) Suspicious adrenal 
mass 
 
Mosharafa 
(2007) 
8,551 
 
360 (4.2%) Simple cyst 
19 (0.22%) Renal Atrophy  
382 (4.5%) Stones  
95 (1.1%) Hydronephrosis 
83 (0.97%) Increased parenchymal 
echogenicity  
 
    
Tosaka (1990) 41,364  
(20,897 
screening and 
20,467 non 
screening) 
82 (0.20%) Cyst 
8 (0.019%) AML 
2 (0.0048%) Other benign neoplasm 
8 (0.019%) Other benign lesion  
12 (0.029%) Sinus lipomatosis 
 
 
Haliloglu (2010)  18,203 
 
35 (0.19%) AML 
3 (0.016%) Indeterminate benign cyst 
 
    
Matthews 
(1982) 
 
100  15 (15%) Cyst 
1 (1%) Small kidney  
 
(*Hydronephrosis data excluded as LUTS 
= Mild hydronephrosis in 5, Severe in 5) 
 
Fields (1985) 500  33 (6.6%) Cyst  
6 (1.2%) Hydronephrosis  
6 (1.2) Stones 
5 (1%) Chronic renal disease  
1 (0.2%) Extrarenal pelvis 
1 (0.2%) Malrotated kidney 
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Bodner (1990) 86 
Spinal cord 
injury patients* 
6 (7.0%) Cyst 
6 (7.0%) Stones 
8 (9.3%) Chronic pyelonephritis 
 
*Hydronephrosis likely overestimated, 
as are 3 Bladder stones and 3 Bladder 
diverticiculae 
 
Al-durazi (2003) 
 
100 9 (9%) Stones 
9 (9%) Cyst 
2 (2%) small kidneys 
 
*Hydronephrosis overestimated in this 
group, as are bladder stones 5 
2 (2%) Bladder cancer 
 
Belani (2004) 600  
 
4 (0.67%) AML  
Heikinnen 
(2005) 
400 1 (0.25%) AML, 
32 (8%) Cysts  
12 (3%) Abnormal kidney 
size/shape/echogenicity 
18 (4.5%) Abnormal renal pelvis/sinus. 
34 (8.5%) Focal renal lesions (not 
specified)  
 
 
Patel (2009) 3,976 
 
 
14 (0.35%) Cyst 
40 (1.0%) Stones 
 
*Hydronephrosis will be overestimated, 
as will be bladder stones 
1 (0.025%) Metastatic 
lymphomatous adrenal lesion 
 
 
Abbreviations: AML=angiomyolipoma; LUTS= lower urinary tract symptoms; TCC= transitional cell carcinoma. 
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Supplementary Table S7 
 
Variable Coefficient Standard error P value 
Study type (screening population, 
incidental finding and mixed) 
0.000087 0.00054 0.876 
Publication year -0.00065 0.000091 <0.0001 
Study quality score  0.00049 0.00059 0.432 
Geographical region 0.0012 0.00027 0.002 
Constant -0.00029 0.00089 0.753 
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